Navigation Links
Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
Date:9/9/2008

WELLESLEY HILLS, Mass., Sept. 9 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all oral drug delivery intellectual property will be sold at a sealed bid auction on October 10, 2008.

Spherics' proprietary anhydride based hydrophobic thermoplastic polymers, Spheromers(TM), have superior conventional hydrophilic bioadhesive polymers. These polymers improve drug performance by increasing absorption and residence time in specific regions of the gastro-intestinal track.

BIOGIT(TM) (BIOadhesive Gastro-Intestinal Targeted system) and BIOROD(TM) (BIOadhesive Rate-controlled Oral Delivery system) were developed at Spherics. These are advanced, bioadhesive polymer-based oral drug delivery systems that offer the flexibility of achieving a variety of drug release profiles and offer advantages in a number of applications:

-- Significantly increasing the bioavailability of drugs that have narrow absorption window

-- Tailored to deliver drug combinations of varying properties either simultaneously or sequentially in a controlled manner

-- Improved and sustained delivery of drugs in the treatment of local GI disorders

-- Alleviate food effect for drugs known to have their PK profiles influenced by meals

-- Tailored to release drug in a delayed pulse or two pulse release manner (chronotherapy)

Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's office -- jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package and access to the Spherics electronic data room.

About Spherics

Spherics has built a strong intellectual property position around its drug delivery technologies and products. The Company has a broad range of issued US and international patents that they have applied to their four centra
'/>"/>

SOURCE Spherics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spherics, Inc. Assigns Assets to Joseph F. Finn, Jr., C.P.A.
2. Spherics, Inc. Successful Bidder May Make NDA Submission
3. Spherics, Inc. Successful Bidder May Make MHRA Submission
4. Spherics, Inc. Offers Once Daily Extended Release Formulation for Sustained and Stable Pramipexole Delivery
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Improving an Integral Part of the Lab: Vacuum 2Improving an Integral Part of the Lab: Vacuum 3Improving an Integral Part of the Lab: Vacuum 4Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 2Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 3Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 4Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 5Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 6Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 7Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 8Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation 9FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses 2FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses 3FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses 4FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses 5FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses 6